This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug, Xtandi, met the primary endpoint in a late-stage study that can expand the label of the drug to include hormone-sensitive patients.
Bristol-Myers to Sell French Consumer Health Unit for $1.6B
by Zacks Equity Research
Bristol-Myers (BMY) receives a $1.6 billion offer for its French consumer health unit from Japanese company, Taisho.
Merck's Keytruda Gets FDA Approval for Rare Skin Cancer
by Zacks Equity Research
Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod
by Zacks Equity Research
Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.
Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer
by Zacks Equity Research
Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.
Merck's Keytruda Gets EU Nod as Adjuvant Therapy for Melanoma
by Zacks Equity Research
Merck (MRK) gains an EU approval for Keytruda as an adjuvant therapy pertaining to adult patients with advanced melanoma.
J&J Okays $5B Stock Buyback Plan, Stock Remains Stressed
by Zacks Equity Research
J&J's (JNJ) board authorizes a $5-billion share repurchase plan. Stock slips 2.9% on Monday, extending a 10% drop on Friday post publication of a controversial Reuters story.
Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU
by Zacks Equity Research
Roche's (RHHBY) investigational oral medicine risdiplam gets PRIME designation for the treatment of SMA.
Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod
by Zacks Equity Research
Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).
J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc
by Zacks Equity Research
A Reuters article says that J&J (JNJ) knew for decades that its baby powders contained asbestos. J&J stock dips 10%.
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
by Zacks Equity Research
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Roche to Create Companion Diagnostic Test for Merck's Keytruda
by Zacks Equity Research
Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
by Zacks Equity Research
Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.
Roche's Tecentriq Gets FDA Approval for First-Line NSCLC
by Zacks Equity Research
Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.
Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend
by Zacks Equity Research
Amgen (AMGN) hikes its quarterly dividend by 10%.
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
Roche's Kadcyla Halves Death Risk in Breast Cancer Study
by Zacks Equity Research
Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
by Zacks Equity Research
IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.
Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.
J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
by Zacks Equity Research
J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.
Roche's Tecentriq Combination Gets Priority Review by FDA
by Zacks Equity Research
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
Roche Announces Positive Data on Venclexta/Venclyxto at ASH
by Zacks Equity Research
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
Celgene (CELG) Announces Various Cancer Data at ASH 2018
by Zacks Equity Research
Celegne (CELG) presents data from several cancer studies at the annual meeting of American Society of Hematology (ASH).
AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
by Zacks Equity Research
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.